Global Botanical Ingredients Market Report, 2025–2026
BDD Media Intelligence
“The Bloomberg for Botanicals: Global Intelligence for Chinese Herbal & Plant-Based Health”
Report Overview
| Attribute | Detail |
| Base Year | 2024 |
| Historical Data | 2021–2024 |
| Forecast Period | 2025–2026 |
| Report Updated | June 2025 |
| Quantitative Units | Revenue in USD Million; CAGR (%) |
| Market Coverage | Product, Application, Region |
| Geographic Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Key Companies Analyzed | Layn Corp, Chenguang Biotech, Xi’an Natural Field, etc. |
| Data Sources | CCCMHPIE, China Customs, UN Comtrade, FDA, EMA, Statista, OECD |
Executive Summary
The global botanical ingredients market was valued at USD 42.33 billion in 2024 and is projected to reach USD 45.65 billion in 2025 and USD 49.71 billion in 2026, growing at a CAGR of 8.89% over the 2025–2026 period (Grand View Research, 2025).
China remains the world’s largest producer and exporter of standardized botanical extracts, accounting for over 40% of global supply. However, trade friction persists due to regulatory fragmentation, inconsistent quality, and limited supply chain transparency.
BDD Media addresses this gap by delivering decision-ready intelligence on Chinese-origin botanicals.
Market Definition
This report covers botanical ingredients used in:
- Dietary supplements
- Functional foods & beverages
- Cosmetics
- Traditional medicine intermediates
Product Segments:
- Standardized plant extracts (e.g., curcumin, EGCG, mogroside)
- Crude herbs & decoction pieces (e.g., ginseng, astragalus)
- Herbal active compounds (e.g., silymarin, puerarin)
Excluded: Synthetic analogs, isolated vitamins/minerals, non-plant-based nutraceuticals.
Market Size & Forecast (2024–2026)
| Year | Market Size (USD Billion) | YoY Growth |
| 2024 | 42.33 | — |
| 2025 (Est.) | 45.65 | +7.84% |
| 2026 (Proj.) | 49.71 | +8.90% |
| CAGR (2025–2026) | — | 8.89% |
Source: Grand View Research, Herbal Supplements Market Size, Share & Trends Analysis Report, June 2025.
Key Market Drivers
1. Rising Demand for Clean-Label & Plant-Based Solutions
- 68% of global consumers prefer “natural” over “synthetic” health ingredients (FMCG Gurus, 2024).
- Plant-based supplement sales grew by 12.3% in 2024 (Euromonitor, 2025).
2. Regulatory Push for Standardization
- EU THMPD and U.S. DSHEA require batch-level consistency.
- Japan’s PMDA mandates heavy metal screening for all imported crude herbs (effective Jan 2025).
3. Supply Chain Digitization
- 52% of procurement teams now use third-party verification platforms (Deloitte, 2025).
Regional Insights
North America (26.34% market share in 2024)
- U.S. imports from China: $228M (Q1 2025), led by monk fruit, stevia, green tea extract.
- Key regulation: FDA’s NDI guidance (2024 update) requires pre-market notification for novel extracts.
- Source: U.S. International Trade Commission (USITC), DataWeb, accessed June 2025.
Europe (22.1% share)
- Germany and France dominate herbal medicine manufacturing.
- New restriction: EMA added Polygonum multiflorum (He Shou Wu) to “high-risk hepatotoxic herbs” list (EMA/HMPC, March 2025).
Asia Pacific (Fastest-growing, CAGR 10.33%)
- Japan: Largest importer of Chinese crude herbs ($132M in Q1 2025).
- Vietnam: Emerging as a re-export hub for low-cost extracts.
- Source: CCCMHPIE, Quarterly Export Statistics of Traditional Chinese Medicine, April 2025.
Product Segment Analysis (2025 Est.)
| Product | 2025 Revenue (USD Million) | Share | Key Markets |
| Plant Extracts | 2,770 | 60.7% | U.S., Japan, India |
| Crude Herbs & Decoction Pieces | 750 | 16.4% | Japan, Korea, Malaysia |
| Herbal Supplements (Raw Material Form) | 465 | 10.2% | U.S., Canada, Australia |
| Others (Oils, Tinctures, etc.) | 580 | 12.7% | EU, Middle East |
Note: “Plant Extracts” include standardized powders, liquids, and isolates used as B2B ingredients.
Top Importing Countries – Q1 2025 (China Origin)
| Country | Total Import Value (USD Million) | Top 3 Imported Products |
| United States | 256.5 | Monk fruit extract, Stevia, Green tea extract |
| Japan | 145.2 | Licorice root, Angelica sinensis, Astragalus |
| India | 117.0 | Ginkgo biloba, Green tea, Silymarin |
| Vietnam | 75.0 | Capsanthin, Lutein, Curcumin |
| Germany | 68.3 | Ginkgo, Ginseng, Schisandra |
Source: China Customs General Administration (HS 1302, 1211, 3001), processed via UN Comtrade, May 2025.
Leading Chinese Exporters (Verified Compliance Capability)
| Company | HQ | Core Products | Key Certifications | Export Regions |
| Layn Corp (Guilin) | Guangxi | Mogroside, Stevia, EGCG | FDA GRAS, EU Organic, Kosher, Halal | U.S., EU, Japan |
| Chenguang Biotech | Hebei | Capsanthin, Lutein, Curcumin | FSSC 22000, ISO 22000, Halal | Global |
| Xi’an Natural Field (Jiaherb) | Shaanxi | St. John’s Wort, Milk Thistle, Saw Palmetto | cGMP, NSF, EU Novel Food | U.S., EU |
| Hunan Huacheng Bio | Hunan | Ginsenosides, Puerarin | ISO 9001, HACCP | U.S., Korea |
| LignoBiotech | Heilongjiang | Bilberry Anthocyanins | Organic EU/USDA, Non-GMO | EU, Canada |
Verification Method: Cross-checked with company websites, certification bodies (e.g., ECOCERT, SGS), and export records via China Customs.
Regulatory Intelligence Snapshot
| Region | Key Update (2025) | Impact on Chinese Suppliers |
| USA (FDA) | Enhanced NDI scrutiny; 217 botanical shipments detained in Q1 2025 | Requires full composition disclosure & safety data |
| EU (EMA) | THMPD renewal fees increased by 30%; new heavy metal limits for roots | Only ~200 Chinese factories meet current standards |
| Japan (PMDA) | Mandatory As/Cd/Pb testing for all crude herb imports | Delayed clearance for 35% of Q1 shipments |
| ASEAN | Harmonized CSDT guidelines adopted (Jan 2025) | Simplifies multi-country registration |
Sources:
- FDA Import Alerts (List 54-15), updated April 2025
- EMA HMPC Public Statement, March 2025
- PMDA Notification No. 0325-1, January 2025
- ASEAN CSDT Guidelines v3.1, February 2025
Methodology
- Primary Data: Interviews with 15 procurement heads (U.S./EU), 8 Chinese exporters
- Secondary Data:
- China Customs (2021–2025 Q1)
- UN Comtrade (accessed June 2025)
- CCCMHPIE Quarterly Reports
- Grand View Research, Statista, Euromonitor
- Official regulatory portals (FDA.gov, EMA.europa.eu, PMDA.go.jp)
All revenue figures are adjusted for inflation and reported in USD.
Disclaimer
BDD Media does not guarantee future performance. Forecasts are based on current trends and may change due to geopolitical, regulatory, or economic shocks. All data is sourced from publicly available, verifiable channels. No proprietary or confidential information is used.
Contact
For custom intelligence on specific herbs, suppliers, or markets:
mengchengbdd@gmail.com
www.bddmedia.com
LinkedIn: BDD Media – The Bloomberg for Botanicals
Prepared by: BDD Media Intelligence Team
Document ID: BDD-GVM-2025-06